Anti-CD168 Antibody [HMMR/8021] (A314603)

Anti-CD168 Antibody [HMMR/8021]

Mouse monoclonal [HMMR/8021] antibody to CD168.

Hyaluronic acid (HA) is a nonsulfated glycosaminoglycan that regulates cell adhesion and migration. HA effects are mediated through two receptors, CD44 (also designated HCAM) and the receptor of hyaluronic acid mediated motility (RHAMM). RHAMM, also designated intracellular hyaluronic acid binding protein (IHABP) and CD168, is a matrix receptor, which is linked to the plasma membrane by a GPI anchor and regulates cell motility. RHAMM expression is upregulated in malignant lymphoid tissues and is subsequently implicated in tumor progression and metastasis formation, as well as signal transduction. Although still unclear, RHAMM is thought to exist as several isoforms ranging in size. A variant isoform, designated v4, is a protein that when over-expressed, is thought to be the cause of transformation and metastasis formation in fibroblasts.

Human breast, breast cancer or placenta.

IHC: 1-2 µg/ml

Human

Recombinant fragment (around Amino Acids 1-250) of human HMMR protein. The exact sequence is proprietary.

Mouse

Monoclonal

HMMR/8021

kappa

Unconjugated

Protein A/G chromatography.

200 µg/ml

85-90 kDa

Liquid

Supplied in 10mM Phosphate Buffered Saline with 0.05% BSA and 0.05% Sodium Azide.

Shipped at 4°C. Upon delivery aliquot and store at -20°C. Avoid freeze / thaw cycles.

CD168 antigen, HMMR, HMMR_HUMAN, Hyaluronan mediated motility receptor, Hyaluronan-mediated motility receptor (RHAMM), IHABP, Intracellular hyaluronic acid-binding protein, MGC119494, MGC119495, OTTHUMP00000196920, Receptor for hyaluronan-mediated motility, RHAMM